Ameritas Advisory Services’s Inovio Pharmaceuticals INO Stock Holding History

Ameritas Advisory Services’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$4	–	2513
2025 Q2	$4	Buy	+2	New	+$4	﹤0.01%	2829
2023 Q2	–	Sell	-134	Closed	-$1.34K	–	1535
2023 Q1	$1.34K	Buy	+134	New	+$2.28K	﹤0.01%	2496

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Advisory Services's INO Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 2 shares — an estimated $4 sold.

Ameritas Advisory Services first reported a position in INO in Q1 2023 and held it in 2 quarters. The position peaked at $1.34K in Q1 2023. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

Ameritas Advisory Services reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Ameritas Advisory Services sold 2 Inovio Pharmaceuticals shares in Q3 2025, an estimated $4.
Ameritas Advisory Services first reported a position in Inovio Pharmaceuticals in Q1 2023 and held it in 2 quarters.
Ameritas Advisory Services's Inovio Pharmaceuticals position peaked at $1.34K in Q1 2023.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.